氟伐他汀联合非诺贝特治疗混合性高脂血症疗效观察

目的探讨小剂量氟伐他汀与非诺贝特联合应用治疗混合型高血脂症的临床疗效及安全性。方法混合型高血脂症患者182例,随机分为3组,即氟伐他汀组（40mg/d,n=60）、非诺贝特组（200mg/d,n=58）、联合治疗组（氟伐他汀40mg/d＋非诺贝特200mg/d,n=64）,治疗12周;观察治疗前后主要血脂水平的达标率及不良反应。结果12周时联合治疗组血清总胆固醇（TC）、低密度脂蛋白胆固醇LDL-C、三酰甘油（TG）下降的幅度均高于单独用药组（P〈0.05）;TC、LDL-C、TG3项全部达标率也高于单独用药组（P〈0.05）。联合治疗的不良反应与单独用药相比无明显增加。结论小剂量氟伐他汀（40mg/d）与非诺贝特（200mg/d）联合治疗混合型高血脂症,较单独用药更有效、更全面地改善各项血脂水平,具有良好的安全性和耐受性。

Efficacy and safety of combination therapy with low-dose fluvastatin and fenofibrate for combined hyperlipidemia

Objective The aim of this study was to evaluate the efficacy and safety of combinaton therapy with low-dose Fluvastatin and fenofibrate in patients with combined hyperlipidemia.Methods 182 patients with combined hyperlipidemia were randomly assigned to receive 40 mg Fluvastatin(n=60)or 200 mg fenofibrate(n=58),or a combination of 40 mg Fluvastatin and 200 mg fenofibrate(n=64)for 12 weeks.Results After 12 weeks treatments,serum TC,LDL-C and TG levels were reduced more significantly in combi-nation therapy group,compared with the two monotherapy groups(P<0.05),combined treatments were well tolerated with no increase in adverse events.Conclusion Combi nation therapy with low-dose Fluvastatin(40 mg/d)and fenofibrate(200 mg/d)is more effective than Fluvastatin or fenofibrate monotherapy in patients with combined hyperlipidemia,and is generally safe and well tolerated.